Thus, targeting FoxO1 and developing strategies for tissue-specific delivery of FoxO1 therapeutics can serve as an effective approach for treating type 2 diabetes mellitus and improving insulin resistance. This evidence concerns the gene FOXO1 and diabetes mellitus.